Creative Realities (NASDAQ:CREX) Stock, Quote.Headers.trade-ideas

Creative Realities

Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to global retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

CELL

CREX

EMKR

LYTS

TRMR

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 100 points on Thursday.

The Dow traded down 0.35% to 34,645.66while the NASDAQ fell 0.59% to 13,395.39. The S&amp;P 500, also fell, dropping, 0.28% to 4,392.16

Dow Tumbles Over 100 Points; LSI Industries Shares Spike Higher

Movers

AHCO

AKTX

AMRS

ASTI

ASUR

BGLC

CALT

CBIO

CHEK

CLEU

DBGI

DTSS

ETAO

GAMB

GMVD

KSCP

KULR

MODD

MSGS

NAII

NICE

NVOS

PLCE

RCRT

SGHC

Sunlight Financial Holdings, Inc. Class A Common Stock

SUNL

TIVC

TRKA

URGN

WOLF

Gainers


	PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash transaction for $1 per share.


Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Thursday.

The Dow traded down 0.15% to 34,714.53 while the NASDAQ fell 0.32% to 13,432.16. The S&amp;P 500, also fell, dropping, 0.06% to 4,401.60.

Crude Oil Moves Higher; Walmart Raises Guidance

Creative Realities Inc

Creative Realities Inc Warrants (09/11/2022)

Crexendo Inc

B. Riley Securities initiates coverage on Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) with a Buy rating and announces Price Target of $33.

Price Target

Initiation

Analyst Ratings

CNTA

B. Riley Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $33

COEP

Coeptis Therapeutics Receives Notification Letter From Nasdaq Hearings Panel Granting Its Request For Continued Listing Through January 15, 2025

General

SYTA

Siyata Mobile Announced That Its SD7 Handsets And VK7 Vehicle Kits Were Purchased And Deployed By A New Customer, Trans-west Security Systems

Raymond James analyst Stephen Laws upgrades Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) from Market Perform to Outperform and announces $34 price target.

Upgrades

SAFE

Raymond James Upgrades Safehold to Outperform, Announces $34 Price Target

SpaceX CEO Elon Musk said on Thursday that the rocket manufacturing company intends to <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights">offer a trip to Mars</a> to anyone who volunteers in the future but warned that the journey might be uncomfortable.
What Happened: &#8220;In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go&#8230;&#8221; Musk wrote on social media platform X in response to former European Union Commissioner Thierry Breton with whom he has a history of sparring now and then.
However, the journey to Mars, Musk warned, will be like a &#8220;long sea voyage.&#8221;
&#8220;&#8230;.it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure!&#8221; Musk said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go, bearing in mind that it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure! Becoming multiplanetary ensures the long-term survival of life.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1836705091446853687?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk aims to take humans to Mars with SpaceX&#8217;s Starship launch vehicle in an attempt to &#8220;make life multi-planetary.&#8221; Musk has previously even envisioned a self-sustaining city on Mars called Terminus.
Why It Matters: Earlier this month, Musk said the first Starships will <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights" target="_blank" rel="noreferrer noopener">head to Mars in two years</a> once the next Earth-Mars transfer window opens.
The first launches to Mars in 2026, Musk then said, will not have a crew onboard and will be aimed at testing the flight's ability to land intact on Mars.
"If those landings go well, then the first crewed flights to Mars will be in 4 years," Musk wrote, pegging the first crewed Starship flights to the neighboring planet for 2028. A self-sustaining city, he said, should be ready in about 20 years. 
Starship, however, is still under development and undergoing test flights. It was last launched in June and the company is <a href="https://www.benzinga.com/news/24/09/40932353/spacex-continues-to-prepare-for-future-starship-flights-despite-delays-in-faa-launch-clearance-elon">now awaiting the green light </a>from the Federal Aviation Administration for its fifth flight test. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40934031/teamsters-opts-to-not-endorse-either-harris-or-trump-for-upcoming-presidential-elections-citing-fail">Teamsters Opts To Not Endorse Either Harris Or Trump For Upcoming Presidential Elections, Citing Failure To Secure Pledges Of Non-Interference In Union Campaigns</a></li>
</ul>
Image generated using Midjourney and official SpaceX photos on Flickr

SPACE

Tech

SpaceX CEO Elon Musk Says Anyone Can Go To Mars With SpaceX But Journey Would Be Like A 'Long Sea Voyage In Centuries Past'

HC Wainwright &amp; Co. analyst Arthur He reiterates Satellos Bioscience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MSCL#TSX">MSCL</a>) with a Buy and maintains C$1.2 price target.

Reiteration

TSX:MSCL

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains C$1.2 Price Target

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

Biotech

Health Care

ACET

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Offerings

Murphy Oil Intends To Offer $600M Of Senior Notes Due 2032

Ahead of the 2024 presidential election, Elon Musk has thrown his support behind Donald Trump, while his employees are reportedly largely backing Kamala Harris, according to recent data.
What Happened: According to OpenSecrets, employees at Tesla Inc. have contributed $42,824 to Harris&#8217; campaign, compared to $24,840 for Trump. Workers at SpaceX have donated $34,526 to Harris, while only $7,652 has gone to Trump. At X, formerly Twitter, employees have given $13,213 to Harris and less than $500 to Trump, Reuters reported on Thursday.
These figures, though relatively small, highlight a political divide between Musk and his workforce. Musk, the world&#8217;s richest man, has promoted Trump on X and criticized left-leaning ideologies as a &#8220;woke-mind virus.&#8221; He did not respond to requests for comment. In 2020, Musk supported President Joe Biden but has since shifted rightward.
Trump has promised to appoint Musk to lead a government efficiency commission if he wins the Nov. 5 election. The OpenSecrets data includes donations from employees, owners, and their immediate family members, as companies themselves cannot donate to federal campaigns.
See Also: <a href="https://www.benzinga.com/news/24/09/40899012/elon-musk-reacts-after-trump-campaign-releases-over-50-examples-of-democrats-rhetoric-that-inspired?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Trump Campaign Releases Over 50 Examples of Democrats&#8217; Rhetoric That &#8216;Inspired Assassination Attempt&#8217;</a>
Many of Musk&#8217;s employees are based in California, a Democratic stronghold, noted Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, a Tesla shareholder and X investor. In July, Musk announced plans to move X and SpaceX headquarters to Texas due to a California gender-identity law, which he called the &#8220;last straw.&#8221; 
Tesla and X have yet to respond to Benzinga&#8217;s queries.
Why It Matters: Musk&#8217;s political stance has evolved significantly over the years. In August, Musk explained his <a href="https://www.benzinga.com/news/24/08/40329702/elon-musk-who-once-queued-for-6-hours-to-shake-obamas-hand-explains-why-hes-now-supporting-trump-my">support for Trump</a>, stating that his track record has been moderate and he has not been particularly political in the past. He revealed this during a conversation with Trump, touching on various topics from immigration to electric vehicles. 
In September, Musk commented on a debate between Trump and Harris, expressing <a href="https://www.benzinga.com/news/24/09/40808912/elon-musk-says-kamala-harris-exceeded-most-peoples-expectations-but-debate-hosts-were-unfair-to-trum">dissatisfaction with the debate hosts</a> and raising concerns about the lack of discussion on the national debt crisis. He also mentioned that Harris exceeded most people&#8217;s expectations during the debate.
Recently, Musk faced backlash for a <a href="https://www.benzinga.com/news/24/09/40890277/elon-musk-says-his-now-deleted-controversial-post-after-latest-trump-assassination-which-was-labeled">controversial post on X</a>, which he later deleted. The post questioned why no one was attempting to assassinate President Joe Biden or Harris, following an assassination attempt on Trump. The White House labeled the post as &#8220;irresponsible.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

TSLA

While Elon Musk Backs Trump For The White House, His Teams At Tesla, X And SpaceX Are Supporting Kamala Harris: Employees Have Reportedly Donated Over $90K To Vice President's Campaign

Raymond James analyst Stephen Laws downgrades NexPoint Real Est Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NREF#NYSE">NREF</a>) from Strong Buy to Market Perform.

Downgrades

NREF

Raymond James Downgrades NexPoint Real Est Finance to Market Perform

This significant grant will fund a key research study over the next several years, advancing preclinical and ultimately, clinical studies of intranasal anti-CD3 as a potential treatment for this devastating neurodegenerative condition.

Financing

TLSA

Tiziana Life Sciences Announced The National Institutes Of Health Have Awarded A $4M Grant To Study Nasal Anti-CD3 For Alzheimer's Disease

Confirmed overall response rate (ORR) was&nbsp;37.5%&nbsp;for pelareorep + paclitaxel and&nbsp;13.3%&nbsp;for paclitaxel.&nbsp;As previously reported, ORRs at week 16 (the trial&#39;s primary endpoint) in the pelareorep + paclitaxel and paclitaxel monotherapy cohorts were&nbsp;31%&nbsp;and&nbsp;20%, respectively.
&quot;The fact that the median overall survival was not reached because more than half the patients were still alive at the end of the study is a remarkable achievement for us,&quot; said&nbsp;Wayne Pisano, Interim CEO and Chair of Oncolytics&#39; Board of Directors.
&nbsp;

ONCY

Oncolytics Reports Clinical Results From BRACELET-1 Study; Says Overall Survival Results Corroborate Results Of Previous Randomized IND-213 Breast Cancer Study

Raymond James analyst Stephen Laws downgrades Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) from Outperform to Market Perform.

Raymond James Downgrades Lument Finance Trust to Market Perform

SLRN

Acelyrin Announced That Results From Its Global Phase 3 Trial Of Izokibep In Moderate-to-severe Hidradenitis Suppurativa Patients Will Be Shared At The 2024 European Academy Of Dermatology And Venereology

Raymond James analyst James Rollyson initiates coverage on Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) with a Strong Buy rating and announces Price Target of $14.

Raymond James Initiates Coverage On Helix Energy Solns Gr with Strong Buy Rating, Announces Price Target of $14

<ul>
<li>In a Phase 1 in healthy subjects, EDG-7500 was well-tolerated without meaningful changes in left ventricle ejection fraction (LVEF).</li>
<li>CIRRUS-HCM single-dose trial of EDG-7500 in obstructive HCM demonstrated robust left ventricular outflow tract (LVOT) gradient reductions without meaningful changes in LVEF.</li>
<li>Company announced dosing of first patients in CIRRUS-HCM 28-day trial.</li>
</ul>

EWTX

Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy

BTIG analyst Jake Fuller upgrades DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) from Neutral to Buy and announces $155 price target.

DASH

BTIG Upgrades DoorDash to Buy, Announces $155 Price Target

EWCZ

European Wax Center Announced Several Strategic Commercial And Operational Updates As The Company Continues To Focus On Its Key Initiatives Of Attracting New Guests, Retaining First-time Guests And Winning Back Lapsed Guests

This platform is intended to enable Plug to access capital by leveraging its equipment asset base and to provide equipment financing solutions to Plug&#39;s customers to support equipment sales growth.&nbsp;
As a first step in this platform, Plug signed three separate sale and leaseback transactions equivalent to ~$44 million&nbsp;with GTL Leasing, a portfolio company of Antin Infrastructure Partners.
These transactions enable Plug to retain access to crucial hydrogen equipment while strengthening its financial position. The funds generated will be reinvested into Plug&#39;s core operations and focused on driving long-term growth and expansion initiatives.
&nbsp;
&nbsp;

PLUG

Plug Power Reveals Establishment Of An Equipment Leasing Platform And Is Targeting Over $150M In The Near To Mid-term

VVOS

Vivos Therapeutics Announced A Registered Offering Of $4.3M Selling 1.36M Shares At $3.15 Per Share

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Finding <a href="https://investorplace.com/stock-types/undervalued-stocks/">undervalued stocks</a> to buy may&nbsp;greatly&nbsp;improve an investing portfolio&rsquo;s ability to capture enormous long-term profits. This piece examines three inexpensive yet potential stocks. Comprehending the underlying principles of these businesses is important since doing so demonstrates their potential for significant future growth. 



These businesses have significantly increased their gross profit and margin due to their noteworthy improvements in operational efficiency. Similarly, they have deliberately increased service revenue,&nbsp;primarily&nbsp;through installations, laying the groundwork for higher-margin subscription income in the future. One of these businesses is progressing with clinical studies and reaching regulatory milestones thanks to significant funding.&nbsp;



Moreover, the research focuses on these companies&rsquo; recent financial performance and strategic actions, shedding light on the reasons behind their outstanding return potential. Identifying and seizing these chances in an unfavorable macro environment is crucial since investing in these stocks allows you to take advantage of their growth potential and diversifies your investment approach.



<h2>Energy Services of America (ESOA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/greenenergy1600b-300x169.jpg" alt="image of a hand holding a bright light bulb outdoors with trees in the background"><div>Source: Shutterstock</div></div>Energy Services of America (NASDAQ:<a href="https://investorplace.com/stock-quotes/esoa-stock-quote/">ESOA</a>) is a leader in providing construction and maintenance services in the energy sector. The company had a solid gross profit and margin boost relative to top-line growth. In Q2 fiscal 2024, the gross profit was&nbsp;<a href="https://www.prnewswire.com/news-releases/energy-services-of-america-reports-fiscal-second-quarter-2024-results-302140139.html#:~:text=Second%20Quarter%20Fiscal%202024%20Financial%20Results&amp;text=Gross%20profit%20was%20%246.2%20million,sales%20mix%20across%20the%20business" target="_blank">$6.2 million</a>, up from $3.9 million in Q2 2023. Thus, the&nbsp;<a href="https://www.prnewswire.com/news-releases/energy-services-of-america-reports-fiscal-second-quarter-2024-results-302140139.html#:~:text=Second%20Quarter%20Fiscal%202024%20Financial%20Results&amp;text=Gross%20profit%20was%20%246.2%20million,sales%20mix%20across%20the%20business" target="_blank">60% boom</a>&nbsp;in gross profit signifies sharp cost control and operational edge.



Additionally, the gross margin increased from&nbsp;<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1357971/000141057824000633/esoa-20240331x10q.htm" target="_blank">7.3% to 8.8%</a>. This increase in gross margin signifies that the business is becoming more adept at turning sales into&nbsp;real&nbsp;profit and uplifting the&nbsp;top line. A sharp sales mix across all business lines led to improved gross profit. Additionally, Energy Services of America has improved its financial performance. Compared to a net loss of $1.9 million in Q2 fiscal 2023, the net loss for Q2 fiscal 2024 was $1.1 million.&nbsp;



In sum, attaining considerable improvements in gross profit and margin makes Energy Services of America a top pick among undervalued stocks to buy.



<h2>Creative Realities (CREX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/real-estate-1600-300x169.png" alt="Real estate agent handing over a house key, desktop with tools, wood swatches and computer on background, top view. Real estate stocks."><div>Source: Stock-Asso / Shutterstock</div></div>Creative Realities (NASDAQ:<a href="https://investorplace.com/stock-quotes/crex-stock-quote/">CREX</a>) engages in digital marketing technology solutions. These include installations and SaaS services. The company had a boost in gross profit from<a href="https://investors.cri.com/news-releases/news-release-details/creative-realities-reports-fiscal-2024-first-quarter-results" target="_blank">&nbsp;$5.1 million</a>&nbsp;in Q1 2023 to $5.8 million in Q1 2024.&nbsp;This&nbsp;indicates a rise in the bottom line. A strategic shift in the revenue mix led to a decline in the gross margin percentage, falling from&nbsp;<a href="https://investors.cri.com/news-releases/news-release-details/creative-realities-reports-fiscal-2024-first-quarter-results" target="_blank">51.2%&nbsp;</a>to 46.9%. Additionally, the company&rsquo;s service top-line increased by a massive 45%, especially in installations. These installations are vital because they bring in higher-margin subscription income down the road.&nbsp;



Moreover, annual recurring revenue (ARR) increased from&nbsp;<a href="https://seekingalpha.com/article/4691887-creative-realities-inc-crex-q1-2024-earnings-call-transcript?source=content_type%3Areact%7Csection%3ATranscripts%7Csection_asset%3ATranscripts%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1" target="_blank">$16.3 million</a>&nbsp;at the end of 2023 to an all-time high of $17.7 million as of Q1 2024. This $1.4 million rise in ARR demonstrates&nbsp;that customers&rsquo; dependence on creative realities&rsquo; technological solutions is expanding. Additionally, the business reiterated its projection to reach an ARR of $20 million by the end of 2024, demonstrating its strong belief in ongoing expansion and client retention.



Overall, Creative Realities&rsquo;s strategic lead toward the bottom line and service revenue supports its presence on the undervalued stocks to buy list.



<h2>Outlook Therapeutics (OTLK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>Outlook Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/otlk-stock-quote/">OTLK</a>) operates a biopharmaceutical company that develops and commercializes treatments. The company is in solid financial standing. The company recently closed a private placement that raised $172 million.&nbsp;This&nbsp;includes&nbsp;<a href="https://ir.outlooktherapeutics.com/node/11621/pdf" target="_blank">$65 million</a>&nbsp;received in cash from the sale of common stock and warrants. With that, there is an additional potential of<a href="https://ir.outlooktherapeutics.com/node/11621/pdf" target="_blank">&nbsp;$107 million</a>&nbsp;contingent on the full exercise of these warrants. This accessible capital&nbsp;is expected&nbsp;to fund the company through critical milestones. Hence, these include the potential approval and commercial launch in parts of Europe, the completion of the NORSE EIGHT study, and the subsequent US launch.&nbsp;



Further, the company is collaborating with Cencora (NYSE:<a href="https://investorplace.com/stock-quotes/cor-stock-quote/">COR</a>) to leverage its infrastructure for the EU launch of ONS-5010. The company plans to&nbsp;<a href="https://seekingalpha.com/article/4693948-outlook-therapeutics-inc-otlk-q2-2024-earnings-call-transcript?source=content_type%3Areact%7Csection%3ATranscripts%7Csection_asset%3ATranscripts%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1" target="_blank">commercialize ONS-5010 directly in the US</a>. Meanwhile, it evaluates direct and partnered commercialization strategies in Europe and other regions. ONS-5010&nbsp;is expected&nbsp;to receive ten years of market exclusivity in the EU if approved.



To conclude, Outlook Therapeutics&rsquo;s high potential involves achieving regulatory approval and progressive product launches, making it a top pick among undervalued stocks to buy.



On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-undervalued-gems-set-to-soar-1000-by-2026/">3 Undervalued Gems Set to Soar 1,000% by 2026</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Undervalued Gems Set to Soar 1,000% by 2026

Creative Realities joins Russell Microcap index

In a report released today, Jason Kreyer from Craig-Hallum maintained a Buy rating on Creative Realities (CREX – Research Report). The company's sh...

Creative Realities (CREX) Receives a Buy from Craig-Hallum

Deep Sail Capital Partners Q2 2024 Investor Letter

Craig-Hallum Reaffirms Their Buy Rating on Creative Realities (CREX)

Craig-Hallum analyst Jason Kreyer maintained a Buy rating on Creative Realities (CREX – Research Report) today. The company's shares closed yesterd...

Creative Realities GAAP EPS of -$0.06 in-line, revenue of $13.1M beats by $0.04M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Creative Realities (NASDAQ:<a href="https://investorplace.com/stock-quotes/crex-stock-quote/">CREX</a>) just reported results for the second quarter of 2024.<ul><li>Creative Realities reported earnings per share of -6 cents. This was above the analyst estimate for EPS of -7 cents.</li><li>The company reported revenue of $13.12 million.</li><li>This was 4.09% better than the analyst estimate for revenue of $12.60 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/crex-stock-earnings-creative-realities-for-q2-of-2024/">CREX Stock Earnings: Creative Realities Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CREX Stock Earnings: Creative Realities Beats EPS, Beats Revenue for Q2 2024

Creative Realities, Inc. (CREX) Q2 2024 Earnings Call Transcript

Creative Realities (CREX) just unveiled an update. Creative Realities, Inc. has amended its Stock Incentive Plan, increasing the available shares f...

Creative Realities Proposes Expansion of Stock Incentive Plan

ACHR

AFRM

ANET

CAVA

ESOA

ESTC

KRKNF

NVDA

OTLK

Press Releases

Creative Realities Reports Fiscal 2024 First Quarter Results

Creative Realities Inc. plans its expansion into EMEA and announces its beta launch to EMEA Integrators in 2024

Creative Realities Closes on New Revolving Credit Facility

Creative Realities to Be Included in Russell Microcap Index

Management

Creative Realities Appoints David Schultz as Vice President, New Business Development

Creative Realities added to membership of Russell Microcap® Index

Creative Realities Expands to LATAM to Accelerate the Booming Digital Signage Market, starting in Mexico

Creative Realities Elevates Game Day with Innovative Digital Signage in Sports & Entertainment Venues

Creative Realities, Inc. Announces Second Quarter 2024 Earnings Release Date and Conference Call Information

Creative Realities Reports Fiscal 2024 Second Quarter Results

CREXW

Able View Global Inc. - Class B Ordinary Shares

Able View Global

AirNet Technology Inc. - American Depositary Shares, each representing one ordinary shares

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Creative Realities

Creative Realities (CREX) Forecast

Creative Realities (NASDAQ:CREX) Stock, Quote.Headers.trade-ideas